Skip to content
HowShorted

PMV Pharmaceuticals, Inc. short interest in 2023

In 2023, PMV Pharmaceuticals, Inc.'s disclosed short interest ran from 20.47% of shares outstanding on 13 Jan 2023 to 3.16% on 29 Dec 2023, a change of -17.31 percentage points. The year's high was 20.47% on 13 Jan 2023 and its low 3.10% on 15 Nov 2023, averaging 13.15% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.05 days on 15 May 2023. Full history: PMV Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PMV Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
20.47% (13 Jan 2023)
End of year
3.16% (29 Dec 2023)
Change
-17.31 pp
High
20.47% (13 Jan 2023)
Low
3.10% (15 Nov 2023)
Average
13.15%
Highest days to cover
26.05 (15 May 2023)
SEC filings marked
8

Every report in 2023

PMV Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202320.47%18.35
31 Jan 202319.57%22.34
15 Feb 202318.37%15.46
28 Feb 202318.41%16.80
15 Mar 202318.20%8.9310-K filed, results (8-K)
31 Mar 202316.01%7.45
14 Apr 202315.13%10.00
28 Apr 202315.34%20.61
15 May 202314.26%26.0510-Q filed, results (8-K)
31 May 202314.34%24.20
15 Jun 202314.41%23.98
30 Jun 202314.81%17.03
14 Jul 202314.72%17.09
31 Jul 202314.39%14.87
15 Aug 202311.32%11.2610-Q filed, results (8-K)
31 Aug 202311.38%14.63
15 Sep 202313.12%14.20
29 Sep 202313.03%15.45
13 Oct 202311.82%4.39
15 Nov 20233.10%2.0610-Q filed, results (8-K)
30 Nov 20233.50%3.99
15 Dec 20233.66%5.06
29 Dec 20233.16%3.16

See also: PMV Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.